1,327 results match your criteria Brachytherapy [Journal]


I seeds implantation for treating residual hepatocellular carcinoma located beneath the diaphragm after transcatheter arterial chemoembolization.

Brachytherapy 2019 Feb 7. Epub 2019 Feb 7.

Department of Radiology, The Affiliated Hospital of Jiangnan University, Wuxi 4th People's Hospital, Jiangsu Province, Wuxi, China.

Purpose: The effect of I seed implantation for the treatment of local residual tumor of hepatocellular carcinoma located beneath the diaphragm (HCC-LBD) after transcatheter arterial chemoembolization (TACE) has not yet been reported. This retrospective study was performed to evaluate the safety and efficacy of I seeds implantation (ISI) for the treatment of residual HCC-LBD after TACE.

Methods And Materials: A total of 18 patients treated with ISI between August 2012 and March 2018 for residual HCC-LBD after single or multiple TACE were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.008DOI Listing
February 2019
1 Read
1.987 Impact Factor

Factors associated with deformation accuracy and modes of failure for MRI-optimized cervical brachytherapy using deformable image registration.

Brachytherapy 2019 Feb 7. Epub 2019 Feb 7.

Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:

Purpose: To identify factors associated with MRI-to-CT image deformation accuracy and modes of failure for MRI-optimized intracavitary high-dose-rate treatment of locally advanced cervical cancer.

Methods And Materials: Twenty-six patients with locally advanced cervical cancer had preimplantation MRI registered and deformed to postimplantation CT images using anatomically constrained and biomechanical model-based deformable image registration (DIR) algorithms. Cervix (primary) and cervix plus 10-mm margin (secondary) were used as controlling regions of interest for deformation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183068
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2019.01.001DOI Listing
February 2019
2 Reads

Understanding the underutilization of cervical brachytherapy for locally advanced cervical cancer.

Brachytherapy 2019 Feb 2. Epub 2019 Feb 2.

Department of Radiation Medicine, University of California San Diego School of Medicine, San Diego, CA. Electronic address:

Purpose: To understand the reasons behind current low utilization of brachytherapy for locally advanced cervical cancer in the United States.

Methods And Materials: A 17-item survey was e-mailed to the American Brachytherapy Society (ABS) listserv of active members in 2018. Responses of attending physicians in the United States were included in the analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.002DOI Listing
February 2019
1 Read
1.987 Impact Factor

Evaluation of bi-objective treatment planning for high-dose-rate prostate brachytherapy-A retrospective observer study.

Brachytherapy 2019 Feb 1. Epub 2019 Feb 1.

Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Purpose: Bi-objective treatment planning for high-dose-rate prostate brachytherapy is a novel treatment planning method with two separate objectives that represent target coverage and organ-at-risk sparing. In this study, we investigated the feasibility and plan quality of this method by means of a retrospective observer study.

Methods And Materials: Current planning sessions were recorded to configure a bi-objective optimization model and to assess its applicability to our clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.010DOI Listing
February 2019

Optimized penile surface mold brachytherapy using latest stereolithography techniques: A single-institution experience.

Brachytherapy 2019 Feb 1. Epub 2019 Feb 1.

University of Toronto, Toronto, Ontario, Canada; Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address:

Purpose: To describe a technique of penile surface mold high-dose-rate (HDR) brachytherapy and early outcomes.

Methods And Materials: Five patients diagnosed with a T1aN0 squamous cell carcinoma of the penis were treated using a penile surface mold HDR brachytherapy technique. A negative impression of the penis was obtained using dental alginate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2019.01.002DOI Listing
February 2019
1.987 Impact Factor

Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).

Brachytherapy 2019 Jan 18. Epub 2019 Jan 18.

Radiation Oncology, UC San Diego School of Medicine, San Diego, CA.

Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cervical cancer. A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques. Conformal external beam therapies such intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cervical cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.11.009DOI Listing
January 2019

Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.

Brachytherapy 2019 Jan 14. Epub 2019 Jan 14.

Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA.

Purpose: The purpose of this study was to study the correlation between intraoperative and postimplant dosimetry. We investigated the correlation between prostate (V) and urethra (D, D) dose limits, and whether it is possible to increase prostate D and V in intraoperative planning without violating postimplant urethra and rectum dose limits.

Methods And Materials: Seventy-nine patients who underwent real-time ultrasound-guided prostate implants using intraoperative planning from 2013 to 2017 were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.004DOI Listing
January 2019
2 Reads

A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.

Brachytherapy 2019 Jan 9. Epub 2019 Jan 9.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

Purpose: External beam radiation therapy (EBRT) with low-dose-rate (LDR) brachytherapy boost has been associated with improved biochemical progression-free survival and overall survival (OS) compared with dose-escalated EBRT (DE-EBRT) alone for unfavorable-risk prostate cancer. However, it is not known whether high-dose-rate (HDR) boost provides a similar benefit. We compare HDR boost against LDR boost and DE-EBRT with respect to OS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.007DOI Listing
January 2019
1 Read

Evaluation of the accuracy of computer-assisted techniques in the interstitial brachytherapy of the deep regions of the head and neck.

Brachytherapy 2019 Jan 9. Epub 2019 Jan 9.

Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Haidian District, Beijing, PR China. Electronic address:

Purpose: We sought to investigate the feasibility and accuracy of computer-assisted techniques in the interstitial brachytherapy of the deep regions of the head and neck.

Materials And Methods: A computer-assisted brachytherapy workflow was applied to 10 patients with tumors in the deep regions of the head and neck. Based on the brachytherapy treatment preplan, we constructed a digital stereotactic model to accurately transfer the virtual plan into the navigation system, and subsequently printed the individual templates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.003DOI Listing
January 2019
1 Read

Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy.

Brachytherapy 2019 Jan 9. Epub 2019 Jan 9.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

Purpose: Although current Delphi Consensus guidelines do not recommend a specific definition of biochemical recurrence after partial gland therapy, these guidelines acknowledge that serial prostate-specific antigen (PSA) tests remain the best marker for monitoring disease after treatment. The purpose of this study was to determine whether PSA velocity at failure per the Phoenix (nadir + 2 ng/mL) definition is associated with metastasis and prostate cancer-specific mortality (PCSM) in a cohort of patients who experienced PSA failure after partial gland therapy.

Methods: Between 1997 and 2007, 285 patients with favorable risk prostate cancer underwent partial prostate brachytherapy to the peripheral zone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.001DOI Listing
January 2019
1 Read

Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (≤60 years) with localized prostate cancer.

Brachytherapy 2019 Jan 8. Epub 2019 Jan 8.

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:

Purpose: To evaluate the oncological and functional outcomes of young men treated with low-dose-rate brachytherapy (BT) for prostate cancer (PCa).

Materials And Methods: 423 men aged ≤60 years with clinically localized PCa were treated with BT ± external beam radiation. Biochemical failure was defined by Phoenix criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.12.005DOI Listing
January 2019
1 Read

Dosimetric study of CO-60 source step size in uterine cervix intracavitary HDR brachytherapy.

Brachytherapy 2019 Jan 4. Epub 2019 Jan 4.

Department of Physics, G.G.D.S.D. College, Chandigarh, India.

Purpose: The present work reports effects of source step sizes on dose distribution in patients treated with cobalt-60 (Co-60) high-dose-rate afterloading brachytherapy in carcinoma cervix (Ca-cx).

Methods And Materials: The retrospective study is based on data of 15 patients of Ca-cx treated with Co-60 high-dose-rate intracavitary brachytherapy with dose of 21 Gy in three fractions with source step size of 2.5 mm after external beam radiotherapy of 46 Gy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183054
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.12.006DOI Listing
January 2019
3 Reads
1.987 Impact Factor

Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.

Brachytherapy 2018 Dec 26. Epub 2018 Dec 26.

Health Sciences University, Sisli Hamidiye Etfal Training and Research Hospital, Radiation Oncology Department, Istanbul, Turkey.

Purpose: To evaluate the effect of metabolic parameters of pretreatment primary tumor and regional lymph nodes with F-18-FDG PET/CT compared with MRI findings for the prognostic value and disease-free survival (DFS) in locally advanced cervical cancer.

Material And Methods: From 2011 to 2016, 112 patients with a diagnosis of cervical cancer stages IB2-IVA treated with concomitant chemoradiation therapy with 3D intracavitary brachytherapy were analyzed. From this group, 50 patients who underwent pretreatment and posttreatment FDG PET/CT and MRI were enrolled. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183006
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.11.005DOI Listing
December 2018
6 Reads

Use of interstitial brachytherapy in pelvic recurrence of cervical carcinoma: Clinical response, survival, and toxicity.

Brachytherapy 2018 Dec 24. Epub 2018 Dec 24.

Department of Obstetrics and Gynecology, University of Campinas (Unicamp), Campinas, Sao Paulo, Brazil. Electronic address:

Purpose: The purpose of this study was to evaluate clinical response, postrecurrence survival, disease-free survival (DFS), and toxicity related to reirradiation in pelvic recurrence of cervical carcinoma.

Methods And Materials: A retrospective cohort study of 45 women undergoing high-dose-rate interstitial brachytherapy (HDR-IB) was conducted from 1998 to 2014. Clinical information, as well as data on the malignancy, primary treatment, HDR-IB technique, and toxicity, was collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.11.002DOI Listing
December 2018
1 Read

MRI-guided adaptive brachytherapy for locally advanced cervix cancer: Treatment outcomes from a single institution in Hong Kong.

Brachytherapy 2018 Dec 20. Epub 2018 Dec 20.

Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong.

Background: Paradigm has shifted from 2D to image-guided adaptive brachytherapy (IGABT) for locally advanced cervix cancer (LACC). Increasing reports from pioneering institutions and large retrospective multicenter series have demonstrated improvements in outcome and reduction in toxicity with IGABT. However, there is scarcity of data on magnetic resonance (MR)-IGABT in Chinese patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.11.007DOI Listing
December 2018
1 Read

Brachytherapy and survival in small cell cancer of the cervix and uterus.

Brachytherapy 2018 Dec 15. Epub 2018 Dec 15.

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO. Electronic address:

Purpose: Small cell cancer involving the cervix and uterus is considered the same rare disease, but management is controversial and disparate. Patterns of care and outcomes in the United States are unclear.

Methods And Materials: Clinical data from patients with small cell cancer of the cervix and uterus were abstracted from the National Cancer Database from 2004 to 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.11.006DOI Listing
December 2018
2 Reads

Long-term results of multicatheter interstitial high-dose-rate brachytherapy for accelerated partial-breast irradiation.

Brachytherapy 2018 Dec 13. Epub 2018 Dec 13.

Département de radio-oncologie, Centre Intégré de Santé et de Services Sociaux de l'Outaouais, Gatineau, Quebec, Canada.

Purpose: The purpose of this study was to report the long-term results of women treated in one center with accelerated partial-breast irradiation (APBI) with interstitial high-dose-rate (HDR) brachytherapy.

Materials And Methods: We analyzed data from women treated in one center with adjuvant interstitial HDR brachytherapy for early-stage breast cancer. Treatment regimen was homogeneous for all women with treatment dose 32Gy in 8 fractions twice daily given to the tumor bed with interstitial HDR brachytherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.11.004DOI Listing
December 2018
1 Read

Development and dosimetric assessment of a patient-specific elastic skin applicator for high-dose-rate brachytherapy.

Brachytherapy 2018 Dec 7. Epub 2018 Dec 7.

Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea; Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address:

Purpose: The purpose of this study was to develop a patient-specific elastic skin applicator and to evaluate its dosimetric characteristics for high-dose-rate (HDR) brachytherapy.

Methods And Materials: We simulated the treatment of a nonmelanoma skin cancer on the nose. An elastic skin applicator was manufactured by pouring the Dragon Skin (Smooth-On Inc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.11.001DOI Listing
December 2018
2 Reads

Subcutaneous spacer injection to reduce skin toxicity in breast brachytherapy: A pilot study on mastectomy specimens.

Brachytherapy 2018 Dec 5. Epub 2018 Dec 5.

Department of Surgery, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.

Purpose: Accelerated partial breast irradiation is a treatment option for selected patients with early-stage breast cancer. Some accelerated partial breast irradiation techniques lead to skin toxicity with the skin dose as a main risk factor. Biodegradable spacers are effective and safe in prostate brachytherapy to protect the rectum. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183055
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.11.003DOI Listing
December 2018
6 Reads

Risk analysis of electronic intraoperative radiation therapy for breast cancer.

Brachytherapy 2018 Nov 29. Epub 2018 Nov 29.

UC San Diego Radiation Medicine and Applied Sciences, La Jolla, CA. Electronic address:

Purpose: To evaluate the process and improve safety of intraoperative radiation therapy (IORT) for early-stage breast cancers treated with electronic brachytherapy.

Methods And Materials: A multidisciplinary team conducted a failure mode and effects analysis (FMEA) for IORT breast cancer treatments by first developing a process map. This map was then used to identify failure modes for all steps in the treatment workflow. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183062
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.10.007DOI Listing
November 2018
5 Reads

Patient-reported sexual adjustment after definitive chemoradiation and MR-guided brachytherapy for cervical cancer.

Brachytherapy 2018 Nov 30. Epub 2018 Nov 30.

Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada; Radiation Medicine Program, University Health Network, Toronto, Ontario, Canada. Electronic address:

Purpose: The treatment of locally advanced cervical cancer with definitive chemoradiation (CRT) is associated with vaginal toxicity and altered sexual satisfaction. This prospective study assessed patient-reported sexual adjustment, vaginal dosimetry, and physician-reported vaginal toxicity in patients with cervical cancer treated with CRT and MR-guided brachytherapy (BT).

Materials And Methods: Between 2008 and 2010, International Federation of Gynecologists and Obstetricians stage IB-IVA patients with cervical cancer receiving definitive CRT were enrolled in a feasibility study assessing MR-guided BT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.09.005DOI Listing
November 2018
3 Reads

The American Brachytherapy Society consensus statement for electronic brachytherapy.

Brachytherapy 2018 Nov 26. Epub 2018 Nov 26.

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH. Electronic address:

Purpose: Brachytherapy is utilized in the treatment of many different malignancies; although traditionally performed with low-dose-rate or high-dose-rate techniques, more recently, electronic brachytherapy (EB) has emerged as a potential alternative. At this time, there are no evidence-based guidelines to assist clinicians in patient selection for EB and concerns exits regarding differences in dosimetry as compared to traditional brachytherapy techniques. As such, the American Brachytherapy Society appointed a group of physicians and physicists to create a consensus statement regarding the use of EB. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183067
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.10.006DOI Listing
November 2018
7 Reads

Impact on treatment time of MRI-based brachytherapy in two implants (4 doses) compared with CT-based brachytherapy in five implants for cervical cancer.

Brachytherapy 2018 Nov 26. Epub 2018 Nov 26.

Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL. Electronic address:

Purpose: Concurrent chemoradiotherapy and brachytherapy is the standard of care for locally advanced cervical cancer. Brachytherapy is an integral part of treatment and has improved overall survival. Research is needed to ascertain the planning modalities and schedules to best use resources and optimize treatment time course. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.10.005DOI Listing
November 2018
14 Reads

Comparison of two iodine-125 brachytherapy implant techniques for the treatment of lung tumor: Preplanning and intraoperative planning.

Brachytherapy 2019 Jan - Feb;18(1):87-94. Epub 2018 Oct 25.

Cancer Therapy and Research Center, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, PR China. Electronic address:

Purpose: To compare preplanning and intraoperative planning methods of lung tumor brachytherapy based on postimplant CT images and dosimetric outcomes.

Methods And Materials: Detailed postimplant evaluations of iodine-125 seed implants were performed in 15 patients using a preplanning technique and in 15 patients treated with an intraoperative planning technique. The implant details, dosimetric parameters, and implant quality indices were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.007DOI Listing
October 2018
3 Reads

Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.

Brachytherapy 2019 Jan - Feb;18(1):8-12. Epub 2018 Oct 25.

Christian-Albrechts-University Kiel, Medical Faculty, Kiel, Germany. Electronic address:

Purpose: High-dose-rate brachytherapy (HDR-BT) for dose escalation in localized prostate cancer has been established as one standard treatment option. However, long-term results at followup (FU) ≥5 years are usually needed to ensure robustness of reported outcomes. Potential benefit of salvage therapy is, nevertheless, higher when relapse is diagnosed early. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.013DOI Listing
October 2018
2 Reads

Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.

Brachytherapy 2018 Nov 19. Epub 2018 Nov 19.

Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, China. Electronic address:

Purpose: The aims of this study were to evaluate treatment responses and predictive factors for overall survival (OS) in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) treated with iodine-125 (I) brachytherapy.

Methods And Materials: Seventy-seven HCC patients with PVTT underwent I brachytherapy after transcatheter arterial chemoembolization. Clinical, laboratory, and radiological evaluation were performed before and after treatment, as well as at 4-6 weeks intervals for 7 years to assess the efficacy and toxicity of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.10.002DOI Listing
November 2018
10 Reads

Prostate brachytherapy under hypnosedation: A prospective evaluation.

Brachytherapy 2019 Jan - Feb;18(1):22-28. Epub 2018 Nov 10.

Department of Anesthesiology, Centre Hospitalier Lyon Sud, Pierre-Benite, France.

Purpose: Hypnosedation (HS) for brachytherapy has been proposed in patients with prostate cancer and has been evaluated.

Materials And Methods: 79 patients were treated with brachytherapy under HS. The Visual Analog Scale questionnaire was used to assess comfort and anxiety and the lowest, mean, and highest level of pain. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183054
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.10.004DOI Listing
November 2018
7 Reads

Individualized 3D-printed templates for high-dose-rate interstitial multicathether brachytherapy in patients with breast cancer.

Brachytherapy 2019 Jan - Feb;18(1):57-62. Epub 2018 Nov 7.

3dific srl, Innovative Startup, University of Perugia, Italy.

Purpose: High-dose-rate, multicatheter interstitial brachytherapy is technically complex and operator-dependent, requiring lengthy training and specialized skills. Furthermore, until the advent of contouring on computerized tomography (CT) images, difficulties existed in locating the target volume precisely. The present article reports the results of a study that aimed at producing and validating a 3D-printed template to aid in target volume localization for multicatheter interstitial brachytherapy in patients with breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.09.007DOI Listing
November 2018
1 Read

A systematic review comparing radiation toxicity after various endorectal techniques.

Brachytherapy 2019 Jan - Feb;18(1):71-86.e5. Epub 2018 Nov 3.

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.

Purpose: A clinical complete response is seen after neoadjuvant chemoradiation for rectal tumors in 15%-20% of patients. These patients can potentially be spared mutilating total mesorectal excision surgery through a watch-and-wait policy. Recent studies show that dose escalation by a radiation boost increases the clinical complete response rate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.10.001DOI Listing
November 2018
14 Reads

Improving brachytherapy efficiency with dedicated dosimetrist planners.

Brachytherapy 2019 Jan - Feb;18(1):103-107. Epub 2018 Nov 1.

Department of Radiation Oncology at Stanford University, Stanford Cancer Institute, Stanford, CA. Electronic address:

Purpose: To investigate the different factors affecting the procedure duration for high-dose-rate brachytherapy for gynecologic malignancies.

Methods And Materials: We prospectively recorded 86 consecutive vaginal cylinder (VC) treatments and 82 tandem and ovoid treatments. Key time points in the brachytherapy process, identity of the planner and checker, number of treatments per day, and fraction number per patient were recorded. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183058
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.10.003DOI Listing
November 2018
9 Reads

Treatment of metastatic, imatinib refractory, gastrointestinal stroma tumor with image-guided high-dose-rate interstitial brachytherapy.

Brachytherapy 2019 Jan - Feb;18(1):63-70. Epub 2018 Oct 29.

Department of Radiology and Nuclear Medicine, Otto-von-Guericke University, Magdeburg, Germany; 2nd Department of Radiology, Medical University of Gdansk, Gdansk, Poland.

Purpose: Evaluation of efficacy and safety of CT- or MRI-guided high-dose-rate interstitial brachytherapy (iBT) in the treatment of advanced, imatinib refractory, metastatic gastrointestinal stroma tumors (GISTs) was the objective of this retrospective study.

Methods And Materials: A cumulative number of 40 unresectable metastases (30 hepatic, 10 peritoneal) were treated with iBT in 10 selected patients with histologically proven GISTs. Six patients had peritoneal disease, and 5 patients were even progressing under sunitinib (second line)-thus iBT was applied as a salvage maneuver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.09.006DOI Listing
October 2018
5 Reads

Standardization and automation of quality assurance for high-dose-rate brachytherapy planning with application programming interface.

Brachytherapy 2019 Jan - Feb;18(1):108-114.e1. Epub 2018 Oct 29.

Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO.

Purpose: To standardize and automate the high-dose-rate (HDR) brachytherapy planning quality assurance (QA) process utilizing scripting with application programming interface (API) in a commercially available treatment planning system (TPS).

Methods And Materials: Site- and applicator-dependent plan quality (PQ) evaluation criteria and plan integrity (PI) checklists were established based on published guidelines, clinical protocols, and institutional experience. User designed C# programs ("scripts") were created and executed through the API to access planning information in TPS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.09.004DOI Listing
October 2018
4 Reads

Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival.

Brachytherapy 2019 Jan - Feb;18(1):29-37. Epub 2018 Oct 22.

Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA. Electronic address:

Purpose: Stage and histology are well-established prognostic factors for cervical cancer, but the importance of age has been controversial and a clear role for this factor has not yet been defined. Thus, we aim with this study to evaluate the significance of age as an independent prognostic factor in women with cervical cancer and evaluate the therapeutic consequences and survival outcomes as they relate to this factor.

Methods And Materials: The Surveillance, Epidemiology, and End Results (SEER) database was used to retrospectively analyze patients diagnosed with cervical cancer from 1973 to 2013 in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338515PMC
October 2018
12 Reads

Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act.

Brachytherapy 2019 Jan - Feb;18(1):115-121. Epub 2018 Oct 21.

Department of Radiation Oncology, Duke University Medical Center, Durham, NC. Electronic address:

Purpose: The Patient Protection and Affordable Care Act called for expansion of Medicaid in 2014. As some states elected to expand Medicaid and others did not, the goal of this study was to determine the effect of Medicaid expansion on the insurance status at cancer diagnosis of brachytherapy patients.

Methods And Materials: Patients aged 19-64 years with breast, cervical, uterine, or prostate cancer treated with brachytherapy from 2011 to 2014 with known insurance status were identified within the Surveillance, Epidemiology, and End Results registry. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183050
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.08.017DOI Listing
October 2018
11 Reads

A prospective analysis of catheter complications for gynecological cancers treated with interstitial brachytherapy in the 3D era.

Brachytherapy 2019 Jan - Feb;18(1):44-49. Epub 2018 Oct 10.

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Purpose: Perineal interstitial brachytherapy (P-ISBT) is an important component in the treatment of locally advanced gynecological cancers. However, there are concerns about potential acute complications from catheter needles. The goal is to evaluate the safety of P-ISBT by studying acute complications and radiological organ needle intrusions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.09.002DOI Listing
October 2018
2 Reads
1.990 Impact Factor

Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.

Brachytherapy 2019 Jan - Feb;18(1):38-43. Epub 2018 Oct 10.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Purpose: The treatment paradigm for uterine clear cell carcinoma is often linked to serous carcinoma. This study compares oncologic outcomes between women with uterine clear cell and serous carcinoma.

Methods And Materials: We reviewed 114 women with stage I-II uterine clear cell carcinoma (n = 17, 15%) or serous carcinoma (n = 97, 85%) who underwent hysterectomy and salpingo-oophorectomy at our institution from April 1992 to December 2011; 86 (76%) had stage IA, 14 (12%) had stage IB, and 14 (12%) had stage II disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183053
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.08.015DOI Listing
October 2018
4 Reads

Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.

Brachytherapy 2019 Jan - Feb;18(1):1-7. Epub 2018 Oct 4.

Department of Radiation Oncology, Mayo Clinic, Rochester, MN. Electronic address:

Purpose: To report outcomes of patients undergoing low-dose-rate (LDR) brachytherapy and investigate factors associated with biochemical failure and survival.

Methods: Consecutive patients undergoing LDR with I-125 at our institution between 1998 through 2013 for primary intact prostate cancer were examined. Those with low- and intermediate-risk disease receiving LDR with a minimum of 2 years followup and at least one post-LDR prostate-specific antigen (PSA) were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.09.003DOI Listing
October 2018
4 Reads

Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy.

Brachytherapy 2019 Jan - Feb;18(1):95-102. Epub 2018 Oct 2.

Department of Medical Physics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Purpose: Identifying dominant intraprostatic lesions (DILs) on transrectal ultrasound (TRUS) images during prostate high-dose-rate brachytherapy (HDR-BT) treatment planning is challenging. Multiparametric MRI (mpMRI) is the tool of choice for DIL identification; however, the geometry of the prostate on mpMRI and on the TRUS may differ significantly, requiring image registration. This study evaluates the efficacy of an in-house software for MRI-to-TRUS DIL registration (MR2US) and compares its results to rigid and B-Spline deformable registration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.006DOI Listing
October 2018
2 Reads
1.990 Impact Factor

Low cardiac and left anterior descending coronary artery dose achieved with left-sided multicatheter interstitial-accelerated partial breast irradiation.

Brachytherapy 2019 Jan - Feb;18(1):50-56. Epub 2018 Sep 24.

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address:

Purpose: Studies have shown that an additional mean dose of 1 Gy to the heart can increase the relative risk of cardiac events. The purpose of this study was to quantify the dose delivered to the heart and left anterior descending artery (LAD) in a series of patients with left-sided breast cancer (BC) or ductal carcinoma in situ treated with multicatheter-accelerated partial breast irradiation (MC-APBI) at a single institution.

Methods And Materials: Patients with left-sided BC or ductal carcinoma in situ treated consecutively from 2005 to 2011 with MC-APBI were retrospectively identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338487PMC
September 2018
14 Reads

Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands.

Brachytherapy 2019 Jan - Feb;18(1):13-21. Epub 2018 Sep 25.

Deptartment of Radiation Oncology Atlanta, GA; Winship Cancer Institute of Emory University, Atlanta, GA.

Purpose: Patients with large prostate glands are underrepresented in clinical trials incorporating brachytherapy due to concerns for excessive toxicity. We sought to compare health-related quality of life (HRQOL) outcomes between small (<60 cc) and large (≥60 cc) prostates treated with high-dose-rate brachytherapy (HDR-B).

Methods And Materials: One hundred thirty patients at Emory University were treated with HDR-B monotherapy (n = 75) or HDR-B in combination with external beam radiation therapy (n = 55). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.009DOI Listing
September 2018
3 Reads
1.990 Impact Factor

Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.

Brachytherapy 2018 Nov - Dec;17(6):899-905. Epub 2018 Sep 21.

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Purpose: To identify patients at extremely low risk of biochemical recurrence (BCR) of prostate cancer after low-dose-rate brachytherapy (LDR-BT) to determine when prostate-specific antigen (PSA) monitoring can be stopped.

Methods And Materials: We retrospectively reviewed clinicopathologic data of patients with prostate cancer who underwent LDR-BT between 2003 and 2011. Of 1569 patients reviewed, 689 (43. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.018DOI Listing
September 2018
3 Reads

Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.

Brachytherapy 2018 Nov - Dec;17(6):837-844. Epub 2018 Sep 21.

Clinical Professor, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; Radiation Oncologist, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.

Purpose: To compare biochemical failure using a prostate-specific antigen (PSA) threshold of >0.2 ng/mL to that using Phoenix threshold (nadir+2 ng/mL).

Methods And Materials: Androgen suppression combined with elective nodal and dose-escalated radiation therapy (the ASCENDE-RT trial) is a randomized control trial in which 276 high-risk and 122 intermediate-risk patients were randomized to (1) a standard arm with 12 months of androgen deprivation therapy, pelvic external beam radiation therapy (EBRT) to 46 Gy, and an EBRT boost (dose-escalated EBRT [DE-EBRT]) to 78 Gy, or (2) an experimental arm which substituted a low-dose-rate prostate brachytherapy boost (LDR-PB). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15384721183054
Publisher Site
http://dx.doi.org/10.1016/j.brachy.2018.08.008DOI Listing
September 2018
20 Reads

Skin dose estimation using virtual structures for Contura Multi-Lumen Balloon breast brachytherapy.

Brachytherapy 2018 Nov - Dec;17(6):956-965. Epub 2018 Sep 17.

Department of Radiation Oncology, University of Utah, Salt Lake City, UT.

Purpose: To propose a workflow that uses ultrasound (US)-measured skin-balloon distances and virtual structure creations in the treatment planning system to evaluate the maximum skin dose for patients treated with Contura Multi-Lumen Balloon applicators.

Methods And Materials: Twenty-three patients were analyzed in this study. CT and US were used to investigate the interfractional skin-balloon distance variations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.010DOI Listing
September 2018
2 Reads

A revised dosimetric characterization of Co BEBIG source: From single-source data to clinical dose distribution.

Brachytherapy 2018 Nov - Dec;17(6):1011-1022. Epub 2018 Sep 15.

Physics Department, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Electronic address:

Purpose: Although the dosimetric characterization of Co BEBIG source can be found in several literature studies, the data sets show major discrepancies and the lack of uncertainty analyses. This study tried to determine an accurate dosimetric data set for this source using Monte Carlo (MC) simulations along with detailed uncertainty analysis. To explore how different dosimetric data sets can make changes in practical situations, clinical dose distributions based on our results were compared with the dose distributions derived from Granero et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.011DOI Listing
September 2018
2 Reads

Accelerated partial breast irradiation with perioperative multicatheter interstitial brachytherapy-A feasibility study.

Brachytherapy 2018 Nov - Dec;17(6):949-955. Epub 2018 Sep 15.

Department of Oncology and Radiotherapy, University Hospital and Medical Faculty, Hradec Králové, Czech Republic.

Purpose: To assess the feasibility of high-dose-rate perioperative multicatheter interstitial brachytherapy to deliver accelerated partial breast irradiation (APBI) in selected patients with early breast cancer.

Methods And Materials: Perioperative multicatheter interstitial brachytherapy for APBI has been used at our department since 2012 for patients with low-risk breast cancer. Interstitial catheters were inserted perioperatively via hollow needles immediately following tumorectomy with sentinel node biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.012DOI Listing
September 2018
4 Reads

Does adjuvant concurrent or sequential chemotherapy increase the radiation-related toxicity of vaginal brachytherapy for endometrial cancer patients?

Brachytherapy 2018 Nov - Dec;17(6):929-934. Epub 2018 Sep 15.

Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL. Electronic address:

Purpose: To compare radiation toxicity in endometrial cancer patients treated with adjuvant vaginal brachytherapy (VBT) vs. VBT with concurrent chemotherapy (CCT) or sequential chemotherapy (SCT) METHODS: We retrospectively analyzed 131 patients with endometrial cancer treated with VBT without external beam radiation therapy. Toxicities were graded according to the Common Terminology Criteria for Adverse Events v4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.005DOI Listing
September 2018
3 Reads

Declining brachytherapy utilization for high-risk prostate cancer-Can clinical pathways reverse the trend?

Brachytherapy 2018 Nov - Dec;17(6):895-898. Epub 2018 Sep 11.

Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA. Electronic address:

Purpose: Although external beam radiation therapy (EBRT) plus a brachytherapy boost (BB) offers a 20% improvement in biochemical progression-free survival compared with dose-escalated EBRT alone for men with intermediate and high-risk prostate cancer, population studies show a concerning decline in BB utilization.

Methods: We modified our clinical pathway (CP) in January 2016 to indicate EBRT with BB as first-choice modality for high-risk prostate cancer, based on preliminary findings of Androgen Suppression Combined with Elective Nodal and Dose-Escalated Radiation Therapy. A retrospective review was performed on 659 patients with high-risk prostate cancer treated with definitive intent EBRT ± BB within a network of 19 sites between December 2011 and July 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.004DOI Listing
September 2018
2 Reads

Evaluation of effective treatment depth in skin cancer treatments with electronic brachytherapy.

Brachytherapy 2018 Nov - Dec;17(6):990-994. Epub 2018 Sep 11.

Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA. Electronic address:

Purpose: To evaluate changes in the percent depth dose (PDD) and effective depth of treatment due to force applied by the applicator during treatments of nonmelanoma skin cancer with the Xoft electronic brachytherapy system.

Methods: To simulate compressible tissue, a 5-mm tissue-equivalent bolus was used. A soft x-ray ion chamber was used for output measurements, which were performed for all Xoft surface applicators with plastic endcaps in place. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.003DOI Listing
September 2018
5 Reads

Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy.

Brachytherapy 2018 Nov - Dec;17(6):858-865. Epub 2018 Sep 11.

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address:

Purpose: To assess the performance of a system of intraoperative dosimetry and obtain estimates of dosimetry outcomes achieved when utilizing the system in a Phase II clinical trial.

Methods And Materials: Forty-five patients undergoing permanent Pd-103 seed implantation for prostate cancer were prospectively enrolled. Seed implantation was performed and dose was tracked intraoperatively using intraoperative registered ultrasound and fluoroscopy (iRUF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.07.013DOI Listing
September 2018
1 Read